Complimentary Webinar from the Predictive Safety Testing Consortium and Merck & Co, Inc
8th August 2017, 5 pm. BST
Presented by John-Michael Sauer, Executive Director, Predictive Safety Testing Consortium, Critical Path Institute & Xuemei Zhao, Senior Principal Scientist, Translational Molecular Biomarkers, Merck & Co., Inc.
Register today, for free: http://bit.ly/2sFP9Sg
Can’t make the dates? Still register and a copy of the recording will be sent to you
Biomarkers form a pivotal role in drug development today and as biomarkers become integrated into drug development and clinical trials, quality assurance and in particular assay validation becomes essential. There is a need for standardised guidelines for analytical methods used in biomarker measurements. Also, new biomarkers used for both the development and use of therapeutics are dependent on the establishment of a solid validation process that addresses technology integration and method validation as well as regulatory pathways for efficient biomarker development. The webinar focuses on the scientific and regulatory considerations for the analytical validation of assays in clinical trials. It will also address recent regulatory updates and the standardisation of validation procedures for efficient biomarker development.
Benefits to attending the webinar:
- Advance your knowledge on Scientific and Regulatory Considerations for Biomarker validation
- Boost your understanding of Analytical Validation of Assays Used in the Clinical Qualification of Biomarkers
Can’t make the dates? Still register and a copy of the recording will be sent to you.
For further information on how to save on your attendance and what discounts we have available please contact email@example.com